InflaRx prioritizes izicopan, slashes workforce, extends cash runway.

InflaRx will focus on izicopan as its leading pipeline asset, aiming to advance Phase 2b trials for hidradenitis suppurativa (HS). The company will conduct a PK bridging study in China to facilitate signal-finding activities in additional I&I indications. InflaRx is reducing its workforce by approximately 30% and extending its cash runway to mid-2027. A virtual Capital Markets Day in spring 2026 will highlight the potential of izicopan in HS and I&I.